Who ClearID Lung can help
This test is designed for patients undergoing treatment for advanced lung cancer. Because it is a blood test, ClearID is especially helpful in situations when a tissue biopsy is not available, difficult to obtain, or when biopsy material is degraded, damaged or considered Quantity Not Sufficient (QNS). Since ClearID is as accurate as a tissue biopsy, it can also be used as a complementary test at initial diagnosis and treatment selection, or during treatment to monitor response and resistance to therapy.
More Information About ClearID Lung Cancer
+ How the test works
ClearID uses molecular analysis to rapidly and precisely generate real-time information on cancer cell activity. These results can greatly aid therapy choice and gene targeting, which includes identification of clinical trials that match the abnormalities found. Because ClearID is able to detect the presence of mutated cells at extremely low levels, it also offers real-time treatment monitoring and potential drug resistance status. Using a simple blood draw, the test can locate even rare populations of cancer cells to report on the following:
- Precise identification of the circulating tumor cell burden
- Targeting and sequencing of genes known to be somatically altered in lung cancer
- Identification and reporting of gene alterations with a known resistance to therapy
+ What your doctor receives
ClearID offers the most clinically relevant and actionable reports available. Within 4 weeks, your doctor will receive a genomic report tailored to your tumor and individual molecular profile. With these results, therapy progress can be more accurately determined and confidently adjusted.
+ How often to re-test
Testing recommendations and frequency will vary by patient. Your doctor can create a schedule that’s right for you.
+ Will insurance cover it?
Cynvenio accepts most insurance plans, and will directly bill the insurance company. Through our ClearBilling program, we also offer several options to help non-insured and underinsured patients. Learn more.